Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Masilukast

Drug Profile

Masilukast

Alternative Names: D 3523; ICI D 3523; MCC-847; SA09012; ZD 3523

Latest Information Update: 15 Jun 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer Mitsubishi Tanabe Pharma Corporation; SAMA Pharmaceuticals
  • Class Antiasthmatics; Bronchodilators; Indoles
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • Discontinued Allergic rhinitis

Most Recent Events

  • 11 Sep 2015 Phase-II development for Asthma is ongoing in South Korea
  • 15 Nov 2012 Masilukast licensed to SAMA Pharmaceuticals in South Korea
  • 15 Nov 2012 Phase-II clinical trials in Asthma in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top